Innovative Therapies in Cancerology
The Graduate School of Innovative Therapies in Cancerology aims to train students in advanced methods and techniques such as immunotherapy, cell therapy and new targeted therapies. The offered training programmes cover the fields of immunology, haematology and oncology.


Presentation
For a long time, surgery, chemotherapy and radiotherapy have been the standard treatments in cancerology. However, innovative approaches such as immunotherapy or adoptive cell therapy based on modified cells have recently emerged and changed the therapeutic field. Extremely rapid clinical advances can be observed thanks to these new T-cell engineering techniques, combination therapies and new knowledge of the immunosuppressive mechanisms of the microenvironment.
Innovative Therapies in Cancerology gives students the opportunity to explore these new therapeutic strategies within the frame of a transversal curriculum combining training in immunology, haematology and oncology. This training is also opened up to healthcare professionals working in hospitals, regulatory agencies or industry in order to prepare them for these innovative treatments in oncology. Students’ internships in research teams associated with Université Paris Cité and in industry developing these molecules will facilitate their professional integration.
Contact
Jean SOULIER
jean.soulier@aphp.fr
Eric TARTOUR
eric.tartour@aphp.fr
Mireille VIGUIER
mireille.viguier@u-paris.fr
Masters
List of Masters taught in French and English:
- Master in Genetics
- M2 BMC – Molecular and Cellular Biology:
List of Masters taught in English:
Research
Various research themes of excellence in immunotherapy and targeted cancer therapy are developed within the laboratories and research teams associated with the Graduate School.
In immunotherapy, the search for biomarkers – allowing the analysis of the tumour microenvironment or molecular biology analysis techniques – and the analysis of the immune response associated with therapies constitute a major and important axis.
Many different targeted therapies have been approved for the treatment of cancer. Their use, in combination with another targeted therapy, helps to overcome the rapid development of specific resistance.
Laboratories
- IRSL – Institut de Recherche Saint Louis
- INEM – Institut Necker-Enfant Malades
- Imagine – Research Group in Computer Vision, Machine Learning and Optimization
- PARCC – Paris Cardiovascular Research Center (Inserm U970)
- Institut Cochin
- CRI – Centre de Recherche sur l’Inflammation (UMR 1149)
- CRC – Centre de Recherche des Cordeliers
- Institut Gustave Roussy
- Hôpital Lariboisière
- IThEm – Innovative Therapies in Haemostasis (UMRS 1140)
- Optimisation Thérapeutique en Neuro-psychopharmacologie (UMRS 1144)
Executives
The governance of the Graduate School of Innovative Therapies in Cancerology is assured by:
- Prof. Jean SOULIER
Professor of Haematology
Saint-Louis Hospital, Inserm, Assistance Publique des Hôpitaux de Paris (APHP)
Université Paris Cité - Eric TARTOUR
Immunologist
Georges-Pompidou European Hospital (HEGP)
Assistance Publique des Hôpitaux de Paris (APHP) - Prof. Mireille VIGUIER
Professor of Immunology
The operational team in charge of the digitisation of the courses and the video transfers on the website is:
- Anne COUEDEL-COURTEILLE
- Magali TERME
À lire aussi

Visite ministérielle dans le cadre de la semaine olympique et paralympique
Dans le cadre de la semaine olympique et paralympique, Édouard Kaminski et le Service Universitaire des Activités Physiques et Sportives (SUAPS) ont eu le plaisir d’accueillir Marie Barsacq, ministre des Sports, de la Jeunesse et de la Vie associative, Philippe...

Varian Pasquet, médaillé olympique et alumni de l’université
Varian Pasquet, alumni 2020 de l'Université Paris Cité, a fait vibrer la France et décroché l’or en rugby à 7 lors des Jeux Olympiques de Paris 2024 et continue de s’illustrer lors du SVNS 2023-2024 la compétition la plus importante du monde de rugby à 7. ...

Avancée majeure et nouvelles perspectives pour les patients atteints de cancer traités pour un événement thromboembolique veineux
Une étude majeure dans la prise en charge des patients atteints de cancer et traités pour un événement thromboembolique veineux (thrombose veineuse profonde, embolie pulmonaire), deuxième cause de décès, a été menée et coordonnée par la Pr Isabelle Mahé, Université...

Appel à projets 2025 UPCité – University of Toronto
L’appel à candidature pour l’année 2025 de l’appel à projets conjoints entre l'Université Paris Cité (UPCité) et notre partenaire privilégié University of Toronto (U of T), est lancé dès ce mardi 1er avril jusqu’au 2 juin 2025. Les objectifsL’Université Paris Cité et...